Michael Mortazie, DO
MOHS-Micrographic Surgery · Orange, CANPI 1457616914
Payments from drug & device makers
Across 397 payments — averaging $3084.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$579K
- Genentech, Inc.$310K
- Amgen$281K
- Janssen Research & Development, LLC$26K
- Novartis$14K
- Sun Pharmaceutical Industries Inc.$11K
- plus $4K from 27 others
What the payments were for
- Consulting fees$11,66540%
- Speaking & faculty fees$10,68036%
- Travel & lodging$1,2924%
- Food & beverage$5,71119%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 113 | $579,039 |
| Genentech, Inc. | 55 | $310,388 |
| Amgen | 15 | $280,581 |
| Janssen Research & Development, LLC | 3 | $25,506 |
| Novartis | 51 | $14,290 |
| Sun Pharmaceutical Industries Inc. | 10 | $10,957 |
| Sanofi | 11 | $457 |
| LEO Pharma Inc. | 19 | $445 |
| AbbVie | 19 | $434 |
| Regeneron Healthcare Solutions, Inc. | 9 | $256 |
| Incyte Corporation | 7 | $224 |
| Janssen Scientific Affairs, LLC | 2 | $220 |
| Almirall LLC | 6 | $203 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 10 | $172 |
| Johnson & Johnson | 9 | $163 |
| Lilly USA, LLC | 7 | $147 |
| Bristol Myers Squibb | 13 | $127 |
| Biofrontera Inc. | 7 | $122 |
| E.r. Squibb & Sons, L.L.C. | 4 | $117 |
| VYNE Pharmaceuticals Inc. | 5 | $117 |
| Galderma Laboratories, L.p. | 5 | $111 |
| Dermavant Sciences, Inc. | 5 | $89 |
| Boehringer Ingelheim | 2 | $55 |
| Krystal Biotech Inc | 1 | $35 |
| Prugen, Inc. Pharmaceuticals | 1 | $31 |
| UCB, Inc. | 1 | $30 |
| Revance Therapeutics, Inc. | 1 | $22 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $20 |
| Botanix SB Inc | 1 | $19 |
| Misonix Inc | 1 | $18 |
| EPI Health, LLC | 1 | $18 |
| Glenmark Therapeutics Inc. | 1 | $17 |
| Journey Medical Corporation | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,224,439 in reported general payments places this provider in the 95th percentile of 144 mohs-micrographic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 574 | $6,777 |
| Gentamicin Sulfate | 23 | $839 |
| Ciprofloxacin Hcl | 126 | $658 |
| Nystatin | 13 | $121 |
| Cephalexin | 13 | $109 |
| Ammonium Lactate | 13 | $100 |
| Mupirocin | 18 | $77 |
| Tramadol Hcl | 19 | $30 |
| Prednisone | 15 | $22 |
| Amoxicillin | 20 | $19 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Orange
- Thuzar ShinSacramento$353K
- Sarah ArronBurlingame$223K
- Christopher Crosbyla Mesa$211K
- Abel TorresLoma Linda$136K
- Robert ScheinbergOceanside$129K
- Sherry RotundaOceanside$99K
- Sumaira AasiStanford$66K
- Daniel Zelacla Jolla$43K
- Ralph MasseySanta Monica$38K
- Robert GoldmanValencia$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.